Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Promethera Biosciences logo — Innovative biopharmaceuticals harnessing healthy human liver...

Promethera Biosciences

Innovative biopharmaceuticals harnessing healthy human liver cells to treat liver diseases with groundbreaking stem cell technology.

Founded 2009 11-50 employees Series D Total: $131.06M Biotechnology, Health and Wellness +1

General Information

Company Name Promethera Biosciences
Founded Year 2009
Employees 11-50
Industries Biotechnology, Health and Wellness, Pharmaceutical
Funding Stage Series D
Social

Get notified when Promethera Biosciences moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Promethera Biosciences

Promethera Biosciences is a biopharmaceutical firm founded in 2009 with a mission to harness healthy human liver cells to develop innovative treatments for liver diseases. The company, originating from the Université Catholique de Louvain, focuses on crafting advanced treatments utilizing allogeneic adult stem cell technology. Their primary goal is the discovery, development, and commercialization of cell therapy products designed to treat liver diseases in an innovative manner through the use of allogenic progenitor cells derived from healthy human livers. Promethera Biosciences has recently garnered a substantial amount of attention in the investment community with a significant Series D investment of €7.50M on 16 December 2019. This investment was made by Pegasus Tech Ventures and Sony Innovation Fund, showcasing that the groundbreaking stem cell technology and innovative approach to treating liver diseases has attracted interest and support from notable investors. With a focus on biotechnology and the pharmaceutical industry, Promethera Biosciences is advancing two products based on a newly identified and patented progenitor cell type: the human Adult Liver-Derived Mesenchymal Progenitor Cell (hALDMSC). This not only demonstrates Promethera Biosciences' commitment to innovation but also underscores the potential of their technological advancements in the medical field.

Taxonomy: Biopharmaceuticals, Cell therapy, Liver diseases, Stem cell technology, Regenerative medicine, Chronic liver disease, NASH, ACLF, Fatty liver, Clinical stage, Liver-based genetic diseases, Innovative treatments, Acquired liver diseases, Antibodies

Funding Rounds & Investors (7)

View All
Funding Stage Amount Investors Lead Investors Date
Series D •••••• 2
Investor Investor
16 Dec 2019
Series D •••••• 2
Investor Investor
30 Jun 2019
Convertible Note •••••• 2
Investor
•••• •••• 		10 Apr 2018
Series C •••••• 7
Investor Investor Investor Investor
•••• •••• 		27 Oct 2016
Series C •••••• 3
Investor Investor
•••• •••• 		25 Nov 2014

View All 7 Funding Rounds

Promethera Biosciences Alternatives & Competitors

Promethera Biosciences vs
Vital Therapies
Vital Therapies

Pioneering the future of liver therapy with innovative cell-based treatments for acute liver failure...

Private Equity
Biotechnology, Health Care
Promethera Biosciences vs
Hexaell Biotech
Hexaell Biotech

Pioneering the future of stem cell and artificial organ technology with breakthrough solutions for l...

Series A
Biotechnology, Health Care
Promethera Biosciences vs
Morphocell Technologies
Morphocell Technologies Canada

Transforming the treatment of liver disease

30 employees
Biotechnology

FAQ About Promethera Biosciences

Innovative biopharmaceuticals harnessing healthy human liver cells to treat liver diseases with groundbreaking stem cell technology.
Promethera Biosciences was founded in 2009.
Promethera Biosciences operates in the following industries: Biotechnology, Health and Wellness, Pharmaceutical.
Promethera Biosciences has approximately 11-50 employees.
Promethera Biosciences has completed 7 funding rounds, raising a total of $131.06M. The latest funding stage is Series D.
Top alternatives and competitors to Promethera Biosciences include Vital Therapies, Hexaell Biotech, Morphocell Technologies, GOLIVER THERAPEUTICS, Hopstem Biotechnology Co., Ltd.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Promethera Biosciences and Vital Therapies are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Promethera Biosciences and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy